Swiss Rockets AG
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
Founded in 2018, the Swiss Rockets Group is an innovative umbrella company with a portfolio of several niche-leading biotech companies ranging from late-stage pre-clinical to Phase III.
Swiss Rockets is dedicated to developing groundbreaking medicines that transform the way cancer, infectious diseases, and autoimmune disorders are treated – striving for a more effective, equitable, and accessible healthcare for patients around the world.
Swiss Rockets AG aims to be one of the leading incubators and accelerators of biotech startups.
Company HQ City:
Basel
Company HQ State:
Switzerland
Company HQ Country:
Switzerland
Year Founded:
2018
Lead Product in Development:
Bimiralisib (PQR309), Solid Tumors & Dermatology
CEO
Dr. Vladimir Cmiljanovic
Development Phase of Lead Product
Phase II
When you expect your next catalyst update?
Q3 2026
What is your next catalyst (value inflection) update?
Advancement of bimiralisib, a topical PI3K/mTOR inhibitor for the treatment of actinic keratosis (AK), into Phase III clinical development.
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}